AD_____

Award Number: DAMD17-03-1-0630

TITLE: Targeting Killing of Breast Tumor Stem Cells

PRINCIPAL INVESTIGATOR: Si-Yi Chen, Ph.D.

CONTRACTING ORGANIZATION: Baylor College of Medicine
Houston, Texas 77030

REPORT DATE: September 2005

TYPE OF REPORT: Final

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. **PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.**

1. REPORT DATE 01-09-2005	2. REPORT TYPE Final	3. DATES COVERED 15 Aug 2003 – 14 Aug 2005
4. TITLE AND SUBTITLE Targeting Killing of Breast Tumor Stem Cells		5a. CONTRACT NUMBER
		5b. GRANT NUMBER DAMD17-03-1-0630
		5c. PROGRAM ELEMENT NUMBER
6. AUTHOR(S) Si-Yi Chen, Ph.D.		5d. PROJECT NUMBER
		5e. TASK NUMBER
		5f. WORK UNIT NUMBER
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Baylor College of Medicine Houston, Texas 77030		8. PERFORMING ORGANIZATION REPORT NUMBER
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012		10. SPONSOR/MONITOR'S ACRONYM(S)
		11. SPONSOR/MONITOR'S REPORT NUMBER(S)

12. DISTRIBUTION / AVAILABILITY STATEMENT
Approved for Public Release; Distribution Unlimited

13. SUPPLEMENTARY NOTES

14. ABSTRACT

It has been postulated that the heterogeneous, metastatic breast cancer cells are originated from a single or a small number of distinct tumor stem cells, and that only the cancer stem cells have the unlimited ability to proliferate and metastasize to different tissues and organs. A recent study found that the CD44+/CD24- breast tumor cells may be breast tumor stem cells. CD44 is a receptor that binds to hyaluronan (HA), a carbohydrate consisting of ß1,3 N-acetyl glucosaminyl-ß1,4 glucuronide. We have proposed to generate CD44-targeted liposome to selectively destroy the CD44+ breast tumor cells. Toward the goal, we have prepared HA molecules from human umbilical cord hyaluronic acid by hydrolysed by Bee venom. However, we have encountered the technical difficulty to produce CD44-targeted liposomes that are incorporated with HA molecules. Due to the technical problems, this proposed study has been extended for additional one year.

15. SUBJECT TERMS
Breast Cancer

16. SECURITY CLASSIFICATION OF:			18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON USAMRMC
a. REPORT U	b. ABSTRACT U	c. THIS PAGE U	UU 5	19b. TELEPHONE NUMBER *(include area code)*

Standard Form 298 (Rev. 8-98)
Prescribed by ANSI Std. Z39.18

Table of Contents

Introduction

Heterogeneous, metastatic breast cancer cells may be originated from a single or a small number of distinct tumor stem cells, and that only the cancer stem cells have the unlimited ability to proliferate and metastasize to different tissues and organs. Such a breast tumor stem cell population was recently identified (1). It was found that only one cell type with high levels of CD44 and low levels of CD24, about 1% to 15%, of breast cancer cells removed from patients were capable of forming new malignant tumors in the nude mice (mammary glands). As few as 100 to 200 of these CD44+/CD24- breast tumor cells readily formed tumors in mice, while tens of thousands of other tumor cells from the same tumor failed to grow, suggesting that the CD44+/CD24- breast tumor cells may be breast tumor stem cells (1).

CD44 is a receptor that binds to hyaluronan (HA), a carbohydrate consisting of ß1,3 N-acetyl glucosaminyl-ß1,4 glucuronide (2). CD44 is found at low levels on a number of cell types in normal tissues, including epithelial, hemopoietic, and neuronal cells. However, these normal cells are either not in direct contact with the blood or require activation before they
bind to HA (2). Thus, CD44 may be a suitable surface marker for targeted killing of breast tumor stem cells that express a high level of this molecule.

Body

The goal of this study is to generate CD44-targeted liposome to selectively destroy the
CD44+ breast tumor cells.

Task 1. To generate and characterize CD44-targeted liposome that is incorporated with
HA.   We have prepared HA molecules from human umbilical cord hyaluronic acid by hydrolysed by Bee venom. Hyaluronic acid fragments were separated on 11 x 265 mm column of the formate form of Bio-Rad AG-3 x 4A ion-exchange resin. However, we have encountered the technical difficulty to produce CD44-targeted liposomes that are incorporated with HA molecules. Due to the technical problems, this proposed study has been extended for additional one year.

We are using the method described by Szoka's laboratory (*Cancer Research* 61, 2592-2601, 2001) to prepare HA-incorporated liposome. Briefly, Chol (Sigma Co. (St. Louis)) was recrystallized from methanol. Lipid films were prepared by drying 10 µmol of lipid including POPE-HA or DPPE-HA from solvent (butanol saturated with distilled water or chloroform:methanol 7:3, respectively) under vacuum using rotary evaporator at room temperature.   Liposomes (composed of POPC:Chol:HA-POPE 60:40:3) were prepared by rehydrating the lipid film with 1 ml of 10 mM HEPES, 5% glucose (pH 7.4), followed by mixing on a vortex mixer for 1 min, sonication for 15 min in a bath type sonicator (Laboratory Supplies Company Inc., Hicksville, NY).

The problem we encountered is that the sizes of HA-liposomes we generated were mostly larger than 0.5 µm, which was determined by light scattering analyses (N4 particle size analyzer, Coulter). The sizes of HA-liposomes are too big to be biologically active (should be in the range of 0.1-0.2 µm). Currently, we are modifying the protocol by testing different experimental conditions in order to achieve a smaller size of liposomes.

Task 2. To evaluate if HA-targeted liposomes (HALs) can selectively bind to the
breast cancer cells expressing high levels of CD44.
To be performed

Task 3. To evaluate if HA-targeted, drug-containing liposomes (HALs) can selectively kill the breast cancer cells expressing high levels of CD44.
To be performed

Key Research Accomplishments

We have generated liposomes containing hyaluronic acids (HA) by using the method described by Szoka's laboratory (*Cancer Research* 61, 2592-2601, 2001). However, there are still in the process to produce HA-liposomes with an average size of 0.1-0.2 µm. The HA-liposomes we generated were too large in sizes (>0.5 µm), and easy to be aggregated. Thus, the HA-liposomes were not suitable for biological evaluation of targeted killing of breast cancer cells.

Reportable Outcomes

The technique to produce HA-liposomes with an average size of 0.1-0.2 µm proves to be difficult. This project has faced this technical hurdle and therefore has yet produced the key materials for testing the targeted killing of breast cancer stem cells.

Conclusions…………………………………………………………………………..4

The technique to produce HA-liposomes with an average size of 0.1-0.2 µm proves to be difficult. The HA-liposomes should be produced by a core facility and a specialized laboratory in order to test the targeted killing of breast cancer stem cells.

References……………………………………………………………………………

N/A

Appendices……………………………………………………………………………

None